齐拉西酮和氯氮平治疗难治性精神分裂症的随机对照研究  

A comparative study of Ziprasidone versus Clozapine in the treatment of treatment-resistant schizophrenia

作　　者：韩从社 王升[1] 宋红梅[1] 张西林[1] 李怀滨 

机构地区：[1]安徽省荣军医院,安徽怀远233400

出　　处：《中国民康医学》2008年第23期2758-2759,共2页Medical Journal of Chinese People’s Health

摘　　要：目的:评价齐拉西酮对难治性精神分裂症的疗效与不良反应。方法:将64例难治性精神分裂症患者随机分为研究组和对照组,分别予齐拉西酮和氯氮平治疗12周,采用PANSS对疗效进行评定,采用TESS和实验室检查对不良反应进行评定。结果:齐拉西酮组有效率为65.6%,氯氮平组有效率为64.5%,两者差异无显著性。不良反应,齐拉西酮组较氯氮平组少而轻,差异显著。结论:齐拉西酮和氯氮平治疗难治性精神分裂症均有良好效果,且疗效相当,齐拉西酮的不良反应少而轻,依从性好。Objective：To evaluate the efficacy and adverse effects of Ziprasidone in the treatment of treatment-resistant schizophrenia.Methods：A total of 64 patients with treatment-resistant schizophrenia were randomly assigned to the Ziprasidone group and the Clozapine group for 12 weeks of treatment.PANSS were used to evaluate the efficacy,TESS and some auxiliary examinations were used to evaluate adverse effects.Results： 65.6% patients in Ziprasidone group and 64.5% patients in Clozapine group had obtained clinical effect.There was no significant deference between two groups.The adverse effect of Ziprasidone group was less and fewer than that of Clozapine group.Conclusions： Ziprasidone and Clozapine are both effective for treating treatment-resistant schizophrenia.Ziprasidone had less and fewer adverse effects and good compliance.

关 键 词：齐拉西酮 氯氮平 难治性精神分裂症 

分 类 号：R749.3[医药卫生—神经病学与精神病学]